1. Home
  2. PHAT vs CCNE Comparison

PHAT vs CCNE Comparison

Compare PHAT & CCNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAT
  • CCNE
  • Stock Information
  • Founded
  • PHAT 2018
  • CCNE 1865
  • Country
  • PHAT United States
  • CCNE United States
  • Employees
  • PHAT N/A
  • CCNE N/A
  • Industry
  • PHAT Biotechnology: Pharmaceutical Preparations
  • CCNE Major Banks
  • Sector
  • PHAT Health Care
  • CCNE Finance
  • Exchange
  • PHAT Nasdaq
  • CCNE Nasdaq
  • Market Cap
  • PHAT 539.5M
  • CCNE 595.8M
  • IPO Year
  • PHAT 2019
  • CCNE N/A
  • Fundamental
  • Price
  • PHAT $8.32
  • CCNE $26.87
  • Analyst Decision
  • PHAT Strong Buy
  • CCNE Hold
  • Analyst Count
  • PHAT 4
  • CCNE 1
  • Target Price
  • PHAT $23.00
  • CCNE $30.00
  • AVG Volume (30 Days)
  • PHAT 992.3K
  • CCNE 46.5K
  • Earning Date
  • PHAT 11-07-2024
  • CCNE 01-21-2025
  • Dividend Yield
  • PHAT N/A
  • CCNE 2.59%
  • EPS Growth
  • PHAT N/A
  • CCNE N/A
  • EPS
  • PHAT N/A
  • CCNE 2.33
  • Revenue
  • PHAT $26,270,000.00
  • CCNE $216,515,000.00
  • Revenue This Year
  • PHAT $7,622.43
  • CCNE N/A
  • Revenue Next Year
  • PHAT $236.87
  • CCNE $8.80
  • P/E Ratio
  • PHAT N/A
  • CCNE $11.53
  • Revenue Growth
  • PHAT N/A
  • CCNE N/A
  • 52 Week Low
  • PHAT $6.07
  • CCNE $17.74
  • 52 Week High
  • PHAT $19.71
  • CCNE $29.29
  • Technical
  • Relative Strength Index (RSI)
  • PHAT 36.67
  • CCNE 48.49
  • Support Level
  • PHAT $7.81
  • CCNE $27.00
  • Resistance Level
  • PHAT $8.56
  • CCNE $27.67
  • Average True Range (ATR)
  • PHAT 0.59
  • CCNE 0.59
  • MACD
  • PHAT 0.22
  • CCNE -0.18
  • Stochastic Oscillator
  • PHAT 38.28
  • CCNE 25.00

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

About CCNE CNB Financial Corporation

CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. In addition, the corporation provides wealth and asset management services, retirement plans and other employee benefit plans.

Share on Social Networks: